New affinity purification technique for therapeutic proteins

July 27, 2020

Professor Kimoon Kim's research group at POSTECH has developed a highly pure and efficient technique for purifying antiviral and anti-cancer protein therapeutics using molecular affinity interaction.

With the COVID-19 showing no signs of slowing down around the world, the development of a vaccine seems to be the sole solution to end the pandemic. However, even if a vaccine is developed, the task of manufacturing well-refined drug molecules, which treat a number of other comorbid conditions, remains elusive. Besides COVID-19, there are growing concerns for developing a source treatment protocol to deal with new infectious diseases that may find their way into our lives.

A joint research team made up of Professor Kimoon Kim (POSTECH University Professor of Department of Chemistry at POSTECH, Director of Center for Self-assembly and Complexity (CSC) and of Institute for Basic Science (IBS)) and Dr. Kyeng Min Park (Research fellow and Group leader at CSC and IBS) have together developed a source technology using the affinity interaction of cucurbiturils to purify recombinant therapeutic proteins used as antiviral drugs or as anti-cancer agents with high efficiency and high purity. The research findings were published online in Nature Biomedical Engineering (DOI: 10.1038/s41551-020-0589-7) on July 20.

Recombinant DNA technology uses biotechnological techniques to insert genes from one organism into another and activate them to change its genetic trait. Using this method, a vaccine can be developed to exterminate pathogenic microorganisms or weaken their toxicity by expressing all or part of the proteins. For the mass-production of the hormones, antibodies or vaccines made from this process, the proteins must be purified.

Until now, therapeutic protein purification technology has used protein-based affinity columns. However, they face financial and technological difficulties as the materials are costly, their storage or reuse is not efficient and their suitability and efficiency depends on the properties of each therapeutic protein.

The researchers succeeded in purifying various types of therapeutic proteins expressed in cells by harnessing the molecular affinity interaction using a synthetic host molecule cucurbit[7]uril (or CB[7] in short), which was first discovered by the same research group. The molecular affinity principle, a key element in the development of the purification technique, is dependent on the high-affinity and controllable host-guest interaction between CB[7] and guests such as adamantane.

The new purification technology has succeeded in purifying a monoclonal antibody drug, Herceptin (breast cancer treatment), as well as much smaller Interferon alpha (leukemia treatment) with high efficiency and high purity.

In particular, by applying small and stable synthetic molecules, the team succeeded in securing the manufacturability, sterilization, and recyclability of purified materials in a stable manner as well as increasing the purity and productivity of purified protein therapeutics. In addition, introducing adamantine (or AdA in short) to therapeutic proteins through genetic regulation and enzyme treatment can purify them regardless of their size or type.

This technique can be applied to most recombinant therapeutic proteins, including antibodies or fusion proteins that effectively prevent or treat fatal diseases such as viral infections or cancer, and is highly efficient and reusable. Furthermore, it is applicable to a wide variety of therapeutic proteins used in the development of vaccines or treatments which will speed up their production.

The research was conducted with the support from the Institute of Basic Science.

Pohang University of Science & Technology (POSTECH)

Related Proteins Articles from Brightsurf:

New understanding of how proteins operate
A ground-breaking discovery by Centenary Institute scientists has provided new understanding as to the nature of proteins and how they exist and operate in the human body.

Finding a handle to bag the right proteins
A method that lights up tags attached to selected proteins can help to purify the proteins from a mixed protein pool.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

New method to monitor Alzheimer's proteins
IBS-CINAP research team has reported a new method to identify the aggregation state of amyloid beta (Aβ) proteins in solution.

Composing new proteins with artificial intelligence
Scientists have long studied how to improve proteins or design new ones.

Hero proteins are here to save other proteins
Researchers at the University of Tokyo have discovered a new group of proteins, remarkable for their unusual shape and abilities to protect against protein clumps associated with neurodegenerative diseases in lab experiments.

Designer proteins
David Baker, Professor of Biochemistry at the University of Washington to speak at the AAAS 2020 session, 'Synthetic Biology: Digital Design of Living Systems.' Prof.

Gone fishin' -- for proteins
Casting lines into human cells to snag proteins, a team of Montreal researchers has solved a 20-year-old mystery of cell biology.

Coupled proteins
Researchers from Heidelberg University and Sendai University in Japan used new biotechnological methods to study how human cells react to and further process external signals.

Understanding the power of honey through its proteins
Honey is a culinary staple that can be found in kitchens around the world.

Read More: Proteins News and Proteins Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to